IN Brief:
- Botanix is allocating new capital to API inventory security and manufacturing resilience.
- The plan includes qualifying an additional API supplier, with onboarding targeted for completion in 2028.
- A second source is intended to reduce single-supplier risk and lower COGS over time.
Botanix Pharmaceuticals has raised approximately A$45 million in new capital with a stated focus on securing its Sofdra supply chain, combining immediate API inventory purchases with a longer-term plan to qualify an additional manufacturing source. The funding structure includes firm commitments for a two-tranche placement of new shares priced at A$0.06 per share, designed to raise about A$40 million before costs, alongside an underwritten security purchase plan targeting up to A$5 million from eligible shareholders.
The placement is split between a first tranche issued within the company’s existing placement capacity and a second tranche subject to shareholder approval at an extraordinary general meeting expected in late March or early April. Botanix has also outlined an intention to offer options to placement and purchase plan participants on a 1:1 basis, subject to shareholder approval, and noted participation by directors and the CEO totalling approximately A$500,000.
A large portion of proceeds is targeted at API and manufacturing component purchases, with Botanix stating it is required to purchase additional API under its existing supply contract and that inventory security is a near-term priority. Beyond purchasing, the company is funding work associated with the set-up of a secondary API supplier, and it has signalled an aim to establish that additional source in a “favourable location, such as North America or Europe,” with onboarding expected to be completed in 2028.
The move reflects the hard reality of pharmaceutical supply: qualifying a second source is neither fast nor cheap, particularly when the product is already commercial and supply continuity matters more than theoretical flexibility. A second supplier typically requires technical transfer, process validation, quality system alignment, and regulatory work to ensure the alternate source is approved and interchangeable without triggering supply disruption.
Botanix has also framed the second-source strategy as a cost lever, stating that the initiative could reduce cost of goods sold by 25 – 40% over time, and referencing patent protection through to 2040 as part of the rationale for investing in a more optimised long-term supply position.
Botanix Executive Chairman Vince Ippolito said: “We expect the targeted funds raised will allow us to derisk our supply chain, secure API under our current supply contract.”
Sofdra is an FDA-approved treatment for excessive underarm sweating, and Botanix is positioning supply resilience as a parallel track to commercial scale. For the supply chain, the immediate impact is concentrated in procurement — securing API and manufacturing components against lead-time risk — while the longer arc depends on the pace at which a second source can be brought through qualification without creating compliance friction or manufacturing instability.
